2022 American Transplant Congress
Use of Pronase to Identify HLA Crossmatch Antibody Interference
*Purpose: Solid organ transplant centers should maintain vigilance that antibody therapies can impact HLA crossmatch results.*Methods: N/A*Results: A 46-year-old man with Mayo stage IV cardiac…2022 American Transplant Congress
The Natural History of De Novo DSA After Kidney Transplantation
*Purpose: De novo donor-specific antibodies(dnDSA) are key in the diagnosis of antibody-mediated rejection(ABMR) and are related to graft loss(GL). Luminex® provides semi-quantitative information with the…2022 American Transplant Congress
Post-Xenotransplant Antibody Specificities Against Swine, Monkey and Human Leukocyte Antigens in Highly Sensitized Nonhuman Primate Model
Surgery, Duke Transplant Center, Durham, NC
*Purpose: Xenotransplantation has been proposed as a bridge to transplant for allosensitized patients. However, the potential of xenotransplantation to broaden HLA allosensitization due to MHC…2022 American Transplant Congress
Immunogenicity of a 3rd Dose of Mrna Covid-19 Vaccine in Kidney Transplant Recipients Who Failed to Respond to 2 Prior Doses
*Purpose: Kidney transplant recipients (KTRs) have diminished immune response and protection after 2-dose mRNA COVID-19 vaccination. It is unknown if additional doses improve neutralization of…2022 American Transplant Congress
Simultaneous Liver/ Kidney Transplant Reduces Both Donor Specific and Non-Donor Specific HLA Antibodies
Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Kidney allografts can be transplanted across strong donor specific antibody (DSA) barriers in simultaneous liver/kidney transplant (SLK) recipients. It is suggested that preformed DSAs…2022 American Transplant Congress
The Role of LAG3 in Antibody Responses to Kidney Transplantation
*Purpose: The functions of coinhibitory receptor lymphocyte activation gene-3 (LAG3) in T cells are well studied, however its role in humoral immune responses remains poorly…2022 American Transplant Congress
Monitoring Efficacy of Tocilizumab Treatment for Chronic Antibody Mediated Rejection (cAMR) in Kidney Transplants Using Donor-Derived Cell-Free DNA (dd-cf-DNA)
*Purpose: IL-6/IL-6R have emerged as important targets for treating cAMR. Recent data show that long-term treatment can stabilize eGFR, reduce DSAs and result in a…2022 American Transplant Congress
Faster B Cell Rebound is Observed Following Xenotransplantation Compared to Allotransplantation in a Highly Sensitized Nonhuman Primate Kidney Transplantation Model
Surgery, Duke Transplant Center, Durham, NC
*Purpose: Xenotransplantation outcomes have been greatly improved due to the advent of genetically engineered pigs and agents targeting the CD40-CD40L signaling pathway. However, studies have…2021 American Transplant Congress
Systematic Screening of Kidney Transplant Patients Points Towards Deficits in Neutralizing Antibody Capacity Against Sars-cov-2
*Purpose: The majority of kidney transplant recipients (KTR) is able to develop SARS-CoV-2 antibodies (Abs). Little is known about the virus neutralizing capacity of these…2021 American Transplant Congress
Successful Prophylaxis of Antibody-Mediated Rejection by Downregulation of C5 Expression via RNA Interference in a Rat Kidney Transplant Model
*Purpose: Antibody-mediated rejection (AMR) is a major contributor towards poor prognosis in kidney transplantation. Circulating donor-specific antibodies (DSAs) cause AMR with complement activation. This study…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 57
- Next Page »